alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 56 studies in Nature Medicine · free to read (page 1 of 3) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 56 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 80 out of 100. Nature Medicine 2023-05-29

An unresolved question for the understanding of Alzheimer's disease (AD) pathophysiology is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) individuals do not develop detectable downstream tau pathology and, consequently, clinical deterioration. 5 key findings →

Design: cohort Participants: 1,016 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A cerebrospinal fluid synaptic protein biomarker for prediction of cognitive resilience versus decline in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 77 out of 100. Nature medicine 2025-03-31

Rates of cognitive decline in Alzheimer's disease (AD) are extremely heterogeneous. 1 key finding →

Design: case-control study Participants: 3,397 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Microglial activation and tau propagate jointly across Braak stages

✓ Peer-reviewed alzhub usefulness score 77 out of 100. Nature medicine 2021-08-26

Compelling experimental evidence suggests that microglial activation is involved in the spread of tau tangles over the neocortex in Alzheimer's disease (AD). 4 key findings →

Design: longitudinal study Participants: 130 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Nature medicine 2024-05-17

p75 neurotrophin receptor (p75 NTR ) signaling pathways substantially overlap with degenerative networks active in Alzheimer disease (AD). 2 key findings →

Participants: 242 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Nature medicine 2022-11-10

A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. 3 key findings →

Participants: 1,325 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Escitalopram for agitation in Alzheimer's dementia: a randomized controlled phase 3 trial

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Nature Medicine 2025-03-25

Citalopram is effective in treating agitation in Alzheimer's dementia (AD), but it is associated with cognitive and cardiac risks, likely due to its R-enantiomer. 5 key findings →

Design: phase-3-trial Participants: 173 Evidence: null result

Full summary, score breakdown and related studies → Original source Free full text

Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Nature medicine 2019-01-21

Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for various cerebral proteopathies. 2 key findings →

Design: cross-sectional Participants: 187 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Nature medicine 2024-02-21

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. 1 key finding →

Participants: 1,422 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Immune and metabolic effects of African heritage diets versus Western diets in men: a randomized controlled trial

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Nature Medicine 2025-04-03

African heritage diets are increasingly being replaced by Western-style dietary patterns because of urbanization, economic development, increased access to processed foods, globalization and changing social norms. 2 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Nature Medicine 2023-04-24

Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. 1 key finding →

Design: phase-1-trial Participants: 46 Evidence: early

Full summary, score breakdown and related studies → Original source Free full text

AI-based differential diagnosis of dementia etiologies on multimodal data

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Nature medicine 2024-07-04

Differential diagnosis of dementia remains a challenge in neurology due to symptom overlap across etiologies, yet it is crucial for formulating early, personalized management strategies. 1 key finding →

Participants: 51,269 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Nature medicine 2021-05-24

A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might provide accurate prediction about the risk of developing Alzheimer's disease (AD) dementia. 2 key findings →

Participants: 340 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1/2 trial interim results

✓ Peer-reviewed alzhub usefulness score 71 out of 100. Nature medicine 2024-05-14

GRN mutations cause progranulin haploinsufficiency, which eventually leads to frontotemporal dementia (FTD-GRN). 4 key findings →

Design: clinical trial Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Nature medicine 2026-02-19

Predicting not just if, but also when, cognitively unimpaired individuals are likely to develop onset of Alzheimer's disease (AD) symptoms would be useful to clinical trials and, eventually, clinical practice. 2 key findings →

Design: cohort Participants: 603 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Brain clocks capture diversity and disparities in aging and dementia across geographically diverse populations

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Nature medicine 2024-08-26

Brain clocks, which quantify discrepancies between brain age and chronological age, hold promise for understanding brain health and disease. 4 key findings →

Participants: 5,306 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Nature medicine 2024-05-06

This study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer's disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. 2 key findings →

Participants: 3,297 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic health: a randomized, crossover trial

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Nature Medicine 2025-08-04

MPF (%WC, −2.06 (95% confidence interval (CI), −2.99, −1.13) and UPF (%WC, −1.05 (95% CI, −1.98, −0.13)) resulted in weight loss, with significantly greater %WC on MPF (Δ%WC, −1.01 (95% CI, −1.87, −0.14), P = 0.024; Cohen’s d , −0.48 (95% CI, −0.91, −0.06)). 2 key findings →

Participants: 55 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 67 out of 100. Nature Medicine 2025-03-31

Insoluble tau aggregates within neurofibrillary tangles are a defining neuropathological feature of Alzheimer’s disease (AD) and closely correlate with clinical symptoms. 2 key findings →

Participants: 108 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed